This randomized controlled trial involved 38 home-dwelling older adults (60-80 years, 31 women) with at least one altered sarcopenia parameter. Participants received phenolic-rich extra virgin olive oil (EVOO) alone or combined with prebiotics (EVOO + PREB), plus co-created dietary and physical activity recommendations, compared to refined olive oil with a placebo. The intervention lasted 12 weeks, with outcomes assessed after cessation.
Main results showed that EVOO + PREB significantly increased muscle measures compared to EVOO alone. For example, in females, quadriceps muscle thickness increased by a mean of 0.230 cm (95% CI [0.008; 0.45], p = 0.044), and rectus femoris cross-sectional area increased by a mean of 0.569 cm (95% CI [-1.0; -0.08], p = 0.024). In all populations, rectus femoris muscle thickness increased by a mean of 0.195 cm (95% CI [0.04; 0.35], p = 0.015). At 12-week follow-up, EVOO and EVOO + PREB increased skeletal muscle mass and appendicular skeletal muscle mass compared to refined olive oil, and EVOO improved quality of life scores in females.
Safety and tolerability were not reported. Key limitations include a small sample size of 38 participants, which limits generalizability, and outcomes based on surrogate measures like muscle mass and ultrasound rather than clinical endpoints. The study design supports an association but does not establish causality beyond this trial. Practice relevance is not reported, but results are specific to older adults with probable sarcopenia and require confirmation in larger studies.
View Original Abstract ↓
BACKGROUND: Management of sarcopenia by nutritional and lifestyle interventions is a challenge. The aim is to assess the effectiveness of a phenolic-rich extra virgin olive oil (EVOO), alone or combined with a prebiotic (PREB) (fructooligosaccharides and inulin), to improve skeletal muscle mass and function in home-dwelling older adults (60-80 years) with at least one sarcopenia parameter altered.
METHODS: A 12-week randomised, double-blind, parallel, placebo-controlled, three-arm clinical trial was conducted. Intervention groups were as follows: (1) refined olive oil (ROO; 30 mL/day; 90-mg caffeic acid) + maltodextrin placebo (7.5 g/day); (2) EVOO (30 mL/day; 296-300-mg caffeic acid) + maltodextrin placebo (7.5 g/day); or (3) EVOO + prebiotic (EVOO + PREB; 30 mL/day + 7.5 g/day). Everyone followed co-created dietary and physical activity recommendations. A 12-week follow-up after intervention cessation was assessed.
RESULTS: Thirty-eight participants (69.6 ± 4.1 years; 31 women) with probable sarcopenia were assigned to ROO (n = 13), EVOO (n = 14) or EVOO + PREB (n = 11) intervention groups. At the end-of-intervention, assessed by ultrasound, EVOO + PREB compared to EVOO significantly increased muscle thickness of the quadriceps in females, mean (95% CI) (0.230 cm [0.008; 0.45], p = 0.044), cross-sectional area of the rectus femoris in all populations (0.827 cm [0.16; 1.5], p = 0.017) and females (0.569 cm [-1.0; -0.08], p = 0.024), and rectus femoris muscle thickness in all population (0.195 cm [0.04; 0.35] p = 0.015) and females (0.179 cm [0.05; 0.31] p = 0.009). Also, EVOO + PREB compared to ROO increased the cross-sectional area of the rectus femoris (0.579 cm [0.07; 1.1], p = 0.026) and rectus femoris muscle thickness (0.133 cm [0.00; 0.27], p = 0.050) in females. At 12-week follow-up, EVOO and EVOO + PREB, compared to ROO, significantly increased skeletal muscle mass and appendicular skeletal muscle mass in all populations assessed by bioelectrical impedance analysis (BIA). Also, EVOO, compared to ROO, significantly increased skeletal muscle mass index and appendicular skeletal muscle mass index. In addition, at 12-week follow-up, EVOO, compared to ROO, improved the overall quality of life score in females.
CONCLUSIONS: Consuming phenolic-rich EVOO, alone or combined with prebiotics, improved muscle mass assessed by ultrasound at the end-of-intervention and by BIA at 12-week follow-up. Further studies are needed to confirm these promising results.
TRIAL REGISTRATION: Registration number: NCT05485402; https://clinicaltrials.gov/study/NCT05485402; registration date: 03/08/2022.